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LRRK2Mitochondria are highly dynamic organelles which fulﬁll a plethora of functions. In addition to their
prominent role in energy metabolism, mitochondria are intimately involved in various key cellular processes,
such as the regulation of calcium homeostasis, stress response and cell death pathways. Thus, it is not
surprising that an impairment of mitochondrial function results in cellular damage and is linked to aging and
neurodegeneration. Many lines of evidence suggest that mitochondrial dysfunction plays a central role in the
pathogenesis of Parkinson's disease (PD), starting in the early 1980s with the observation that an inhibitor of
complex I of the electron transport chain can induce parkinsonism. Remarkably, recent research indicated
that several PD-associated genes interface with pathways regulating mitochondrial function, morphology,
and dynamics. In fact, sporadic and familial PD seem to converge at the level of mitochondrial integrity.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD), the most common movement disorder
and the second most common neurodegenerative disease after
Alzheimer's disease, is characterized primarily by the loss of
dopaminergic neurons in the substantia nigra pars compacta leading
to a dopamine deﬁcit in the striatum. The consequent dysregulation of
basal ganglia circuitries accounts for the most prominent motor
symptoms, including bradykinesia, hypokinesia, rigidity, resting
tremor and postural instability. In addition to the typical motor
symptoms, various non-motor features may develop, such as
autonomic dysfunction, sleep disturbances, depression and cognitive
impairment, indicating a more widespread degenerative process. A
pathological hallmark of sporadic PD is the presence of proteinaceous
deposits within neuronal perykarya (Lewy bodies) and processes
(Lewy neurites), mainly composed of α-synuclein, ubiquitin, neuro-
ﬁlaments and molecular chaperones [1]. The role of Lewy bodies in
the disease process and their status as a pathognomonic marker of PD
is still a matter of discussion. Notably, Lewy bodies are not a consistent
ﬁnding in familial forms of PD, therefore it has been proposed to
classify genetic cases as parkinsonism [2].
Little is known about the etiopathogenesis of PD. The most
common sporadic form of PD seems to be a complex multifactorial
disorder with variable contributions of environmental factors and
genetic susceptibility. Aging is the most important risk factor, thus
with increasing average life expectancy the incidence and prevalencex: +49 89 2180 75415.
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ll rights reserved.of PD will rise considerably in the next future. A major breakthrough
in PD research was the identiﬁcation of genes which are responsible
for monogenic familial forms. Mutations in the genes encoding α-
synuclein and LRRK2 (leucine-rich repeat kinase 2) are responsible for
autosomal dominant forms of PD, presumably by a gain-of-function
mechanism. Loss-of-function mutations in the genes encoding parkin,
PINK1, and DJ-1 mediate autosomal recessive PD. Sporadic and
monogenic forms share important clinical, pathological and biochem-
ical features, notably the progressive demise of dopaminergic neurons
in the substantia nigra. Therefore, insight into the function and
dysfunction of PD-associated gene products can help to elucidate the
underlying mechanisms leading to neuronal cell death. Accumulating
evidence indicates that PD-associated genes directly or indirectly
impinge on mitochondrial integrity, thereby providing a link to
pathopysiological alterations observed in sporadic PD (rev. also in
refs. [3–10]). In the following we provide a synopsis of the current
knowledge about the role of mitochondria in sporadic PD and familial
parkinsonism.
1.1. Sporadic PD and mitochondria
1.1.1. Complex I deﬁciency
1.1.1.1. Lessons from an illicit drug. In the late 1970s/early 1980s
young drug addicts in the United States developed progressive and
irreversible parkinsonism after using an illicit drug intravenously. The
neurotoxic compound was traced back to MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine), a by-product generated accidentally
during the synthesis of a meperidine analog [11,12]. One of these
patients, a chemistry graduate student who died of a drug overdose 2
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ation of the substantia nigra pars compacta without a clear evidence
for the presence of Lewy bodies [12]. These ﬁndings were conﬁrmed
when three more patients came to autopsy 3–16 years after MPTP
intoxication [13]. A PD-speciﬁc pattern of nigrostriatal degeneration
without typical Lewy body pathology has also been observed in non-
human primates treated with MPTP [14–17]. Importantly, both the
beneﬁcial and long-term adverse effects of L-dopa therapy in MPTP-
intoxicated patients/non-human primates are comparable to those in
patients suffering from sporadic PD. The neuropathological and
clinical similarities between MPTP-induced parkinsonism and spo-
radic PD promoted the employment of the MPTP monkey model for
neuropathological, neurophysiological and preclinical therapeutical
studies (rev. in ref. [18]). For reasons of practicability, theMPTPmodel
has also been established in mice, which is now widely used to study
some aspects of PD (see refs. [18–24] for detailed reviews on PD
animal models).
In parallel to neuropathological studies in MPTP-treated animals,
considerable efforts have been made to understand the molecular
mechanism of MPTP-induced neurotoxicity. It turned out that MPTP
crosses the blood–brain barrier by virtue of its high lipophilicity and is
oxidized to a pyridinium species by monoamine oxidase (MAO) B in
glial cells [25,26]. This species is further oxidized to the toxic molecule
MPP+, which is released by an unknownmechanism and can be taken
up into dopaminergic neurons via the dopamine transporter [27].
Within neurons MPP+ is concentrated in mitochondria and inhibits
complex I (NADH:ubiquinone oxidoreductase) of the electron
transport chain [28,29]. As a consequence of impaired electron ﬂux
through complex I, mitochondrial ATP production is decreased while
the generation of reactive oxygen and nitrogen species is increased
[30–36]. The downstream events leading ultimately to neuronal cell
death seem to be complex and involve activation of pro-apoptotic
Bcl-2 family members, p53, JNK, and caspases as well as inﬂammation
[18,37–43].
Insights into the molecular actions of MPTP brought up the
question whether complex I activities might be impaired in patients
suffering from sporadic PD. Indeed, complex I activities were reported
to be signiﬁcantly reduced (in the range of 30%) in post-mortem
substantia nigra of PD patients [44–47], and platelets from PD patients
[48–51], while data from skeletal muscle and other non-neuronal
tissues are not consistent [52–56]. Although the complex I deﬁciency
was ﬁrst reported to be speciﬁc for the substantia nigra [57], a 30%
reduction in complex I activity was recently detected also in frontal
cortex mitochondria from PD postmortem brain [58,59]. Interestingly,
Keeney et al. could demonstrate that catalytic subunits of complex I
derived from PD frontal cortexmitochondria are oxidatively damaged,
correlating with complex I misassembly and dysfunction [59].
Whether this increase in oxidative damage is speciﬁc for complex I
and which subunits are affected has not been addressed so far.
In conclusion, several lines of evidence substantiated a link
between PD and complex I activity. Discrepant reports on complex I
activities in PD patients may best be explained by methodological
issues, in particular sample preparation and assay technique. It is also
conceivable that variations in the extent of complex I deﬁciency or
differences between brain and peripheral tissues reﬂect the fact that
PD is not a uniform entity, but rather an etiologically and patholog-
ically heterogeneous syndrome.
1.1.1.2. Complex I and oxidative stress. Transport of electrons through
complexes I–IV in the innermitochondrialmembrane involves a series
of coupled redox reactions, which provide the energy to create a
proton gradient across the inner mitochondrial membrane. Reducing
equivalents from catabolic processes enter the electron transport
chain (ETC) as NADH (at complex I) or FADH2 (at complex II).
Electrons from NADH or FADH2 are passed on in a stepwise fashion
until they reduce oxygen to water at complex IV. The movement ofprotons from the mitochondrial matrix to the intermembrane space
creates an electrochemical gradient across the inner mitochondrial
membrane. The electrochemical gradient, also called proton-motive
force, is composed of a pH gradient (ΔpH) and an electrical potential
(Δψ) anddrives ATP synthesis fromADP as protons re-enter thematrix
through the ATP synthase (complex V). The whole process is called
oxidative phosphorylation.
Complex I is themain gateway for electrons to enter the respiratory
chain (rev. in refs. [60,61]). It consists of 14 central and up to 32
accessory subunits, which form an L-shaped complex with a mem-
brane arm and a peripheral arm protruding into the mitochondrial
matrix. Seven hydrophobic subunits forming the membrane central
core are encoded by mitochondrial (mt) DNA. Complex I catalyzes the
electron transfer from NADH (derived from the tricarboxylic acid
cycle) to ubiquinone involving a ﬂavine mononucleotide (FMN) and
seven iron–sulfur clusters. This activity is coupled to the pumping of
four protons across the innermitochondrial membrane and thus to the
formation of an electrochemical membrane potential. Remarkably, the
reaction catalyzed by complex I is fully reversible, a fact that helps to
explain reverse electron transport (see below) [62,63].
A plethora of studies established that mitochondria are an
important source of reactive oxygen species (ROS) (rev. in refs.
[64–66]). Increased formation of mitochondrial ROS and/or defective
ROS removal by mitochondrial defence systems results in oxidative
damage to mtDNA, proteins and lipids and perturbs redox signaling
pathways [67]. Oxidative damage to mtDNA may compromise
respiratory chain subunits encoded by mtDNA, thereby establishing
a vicious circle of oxidative stress and bioenergetic failure, which has
been the rationale for the mitochondrial theory of aging [68,69]. The
extent, sources and mechanisms of mitochondrial ROS production as
well as its physiological and pathophysiological relevance is still a
matter of intense discussion (rev. in refs. [70–73]). There is increasing
evidence that ROS are not just the bad guys, but have physiological
functions as signaling molecules in diverse cellular pathways (rev. in
refs. [74–76]). Moreover, a mild increase in ROS formation may
activate protective stress response pathways [77,78]. Hence, the
common paradigm that mitochondrial dysfunction is intimately
linked to increased oxidative stress which promotes aging and
neurodegenerative diseases is not unequivocally accepted. Several
aspects have to be taken into consideration which might help to
explain some controversial ﬁndings: First, mechanistic and quantita-
tive studies on mitochondrial function in vivo are technically
demanding, as many of the parameters are highly dynamic. Therefore
most studies on mitochondrial ROS production have been performed
with isolated mitochondria, submitochondrial particles or puriﬁed
ETC complexes. It is now widely accepted that experimental
conditions, such as the nature of substrates, oxygen concentration in
the medium and respiration status strongly inﬂuence the results.
Second, results from studies using isolated ex vivo mitochondria
cannot easily be transferred to the in vivo situation, as the metabolic
state of mitochondria seems to be highly variable and dynamic and in
addition is inﬂuenced by spatial and temporal differences in the
intracellular environment. These considerations are particularly
important for neuronal mitochondria, which can be located at
subcellular sites with different energy requirements and rapid
changes in signaling molecules, such as axons and dendrites. Third,
genetic mouse models might display unexpected or misleading
phenotypes due to a strong compensatory capacity.
Complex I and to a lower extent complex III of the ETC are
considered to be the main sites of ROS production which results from
the transfer of a single electron to oxygen to generate the superoxide
anion. The superoxide anion is the proximal mitochondrial ROS
mainly produced in the mitochondrial matrix, where it is rapidly
converted to hydrogen peroxide catalyzed by MnSOD. In the presence
of metal ions such as Fe2+, hydrogen peroxide can be converted to the
highly reactive hydroxyl radical (Fenton reaction). The amount of
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by a plenitude of factors: the nature of substrates, the potential at the
inner mitochondrial membrane, the pH in the matrix and the local
oxygen concentration (rev. in refs. [64,66,67]). The following condi-
tions favor ROS production at complex I: (1) a low ATP production
leading to a high proton-motive force and a reduced ubiquinone pool;
and (2) a high NADH/NAD+ ratio in the matrix, for example when the
respiratory chain is damaged or the ATP demand is low. In
mitochondria that actively produce ATP and therefore have a lower
proton-motive force (ΔpH and Δψ) and NADH/NAD+ ratio, ROS
production is low. ROS formation at complex I is signiﬁcantly
increased during reverse electron transport which occurs when
electron supply from succinate (increased during exercise and in
hypoxic tissue), glycerol-3-phosphate or fatty acid oxidation reduces
the ubiquinone pool and forces electrons from ubiquinol uphill to
complex I under conditions of a high proton-motive force. Under
these conditions NAD+ is reduced to NADH and ubiquinol is oxidized
to ubiquinone at complex I.
The cause and the consequences of complex I deﬁciency in PD are
not well understood. It has been suggested that mutations in complex
I genes in the mitochondrial or nuclear genome can account for a
dysfunction in complex I activity, assembly and/or stability. Many
studies on complex I inhibition and ROS formation have been
performed with rotenone, an inhibitor of complex I that binds in
proximity to the quinone-binding site. When pyruvate or glutamate
plus malate are used as substrates to generate NADH and induce
forward electron transport, rotenone blocks proton pumping and
increases superoxide generation [79]. During reverse electron
transport, for example when succinate is used as a substrate, rotenone
can block superoxide formation. In addition to the substrates present,
the components of the proton-motive force (ΔpH and Δψ) across the
mitochondrial inner membrane have a strong impact on superoxide
production with a more alkaline pH or a high membrane potential
favoring ROS production [65,79].
Increased oxidative damage has been observed in several cellular
and animal models of drug-induced complex I inhibition [30–35,80]
(for reviews, see refs. [73,81–83]). In this context it is interesting to
note that the ﬁrst genetic mouse model for complex I deﬁciency has
recently been published [84]. Mice lacking the NDUFS4 gene (NADH:
ubiquinone oxidoreductase iron–sulfur protein 4) developed progres-
sive encephalomyopathy at 5weeks of age leading to death at 7weeks.
The abundance of intact complex I and complex I-driven oxygen
consumption were signiﬁcantly reduced, indicating that NDUFS4 may
help to assemble and/or stabilize complex I. Remarkably, ATP levels
were in the normal range and total oxygen consumption was
unaffected in NDUFS4 knockout mice. Moreover, the authors of this
study reported that they did not observe increased ROS formation in
neuronal cultures derived from these mice. To add another layer of
complexity, primary mesencephalic cultures from NDUFS4 knockout
mice did not show an increased rate of cell death.Moreover, theywere
not protected from cell death induced by MPP+ and rotenone [85].
These ﬁndings are surprising as they do not support the link between
complex I deﬁciency, ATP depletion, oxidative stress and dopaminer-
gic neuron death, which has been put forward to explain pathophys-
iological events leading to PD. A plausible explanation would be that
these mice do not reﬂect the gradual decline in complex I activity
which may persist over decades during the pathogenesis of PD in an
aging individual. However, it mightwell be that complex I inhibition is
not primarily responsible for the toxicitiy of MPP+ and rotenone in
dopaminergic neurons. Clearly, more in vivo models are needed to
address the role of complex I deﬁciency in PD.
2. Mitochondrial DNA mutations
MtDNA is a double-stranded circular genome of about 16.6 kb,
which replicates independently from the cell cycle and nuclear DNAreplication. It encodes 13 proteins, all of which are subunits of
respiratory chain complexes: seven subunits of complex I, one subunit
of complex III, three subunits of complex IV and two of ATP synthase.
In addition, mtDNA codes for 22 tRNAs and two rRNAs that are
necessary for mitochondrial protein synthesis (rev. in refs. [86]).
Mitochondria contain about 1500 different proteins, thus the majority
of mitochondrial proteins is encoded by nuclear DNA, translated in the
cytoplasm and imported into mitochondria by an elaborate import
machinery (for review see refs. [87–89]). The multiple copies of
mitochondrial DNA (1000–10,000 per mitochondrion) are arranged
in nucleoids, which consist of several mtDNAmolecules together with
proteins necessary for mitochondrial replication and transcription,
such as the mitochondrial transcription factor A (TFAM). MtDNA is
characterized by an increased vulnerability to mutations, based on
less efﬁcient DNA repair mechanisms and the absence of protective
histones. In addition, the proximity of the respiratory chain has been
suggested to favor mtDNA damage by ROS. MtDNA mutations are
inherited maternally or acquired. The high copy number confers some
protective genetic redundancy, and usually, point mutations or large-
scale deletions of the mtDNA co-exist together with wildtype mtDNA
within a single mitochondrion, a condition which is known as
heteroplasmy (rev. in refs. [70,86,90]). By a process called clonal
expansion the mtDNA mutations can spread to daughter mitochon-
dria and daughter cells (in mitotic tissue), leading to respiratory
deﬁciency when a certain threshold of mutant mtDNA is exceeded
[91]. Typically, mutations in the mitochondrial genome cause
symptoms in postmitotic cells with high energy demands, in
particular neurons and skeletal and cardiac muscle cells, resulting in
encephalomyopathies (rev. in refs. [86,90,92]). However, accumula-
tion of somatic mtDNA mutations occur also during aging in various
tissues, such as brain and muscle (rev. in refs. [70,71]).
An age-dependent increase in somatic mtDNA deletions associ-
ated with a respiratory chain defect has been identiﬁed in
dopaminergic neurons from the substantia nigra by using long-
range PCR and quantitative real time or single molecule PCR [93,94].
Different neurons from the same individual showed unique mtDNA
deletions, implying that they originated from clonal expansion. High
levels (N60%) of mtDNA deletions were found in neurons deﬁcient
for cytochrome c oxidase (COX, complex IV), three catalytic subunits
of which are encoded by mt DNA. These observations suggest that
the increase in mtDNA deletions above a critical threshold might be
causally related to respiratory chain deﬁciency. Bender et al.
reported that levels of mtDNA deletions were slightly higher in
dopaminergic neurons from PD patients in comparison to age-
matched controls. Accumulation of mtDNA deletions was not
observed in hippocampal neurons, pyramidal neurons of the cerbral
cortex or cerebellar Purkinje cells of aged individuals, indicating a
highly speciﬁc process. Interestingly, there seems to be no differ-
ences in the nature of aging- or disease-related mtDNA deletions
detected in single substantia nigra neurons [95]. It will now be
important to address the question why dopaminergic neurons of the
substantia nigra are particularly vulnerable to mtDNA deletions.
Both, the high oxidative burden within these cells and defective
mtDNA replication could contribute to this selective vulnerability. In
this context it may be interesting to note that patients with
mutations in the gene encoding mitochondrial DNA polymerase
(POLG) accumulate multiple mtDNA mutations and develop parkin-
sonism [96]. In addition, variants in the POLG CAG-repeat region,
encoding a polyglutamine tract, seem to be a predisposing factor in
sporadic PD [97].
A link between mtDNA and neurodegeneration has further been
substantiated by genetic mouse models. A conditional knockout of
TFAM in midbrain dopaminergic neurons caused reduced mtDNA
expression, respiratory chain deﬁciency and neuronal cell death,
leading to progressive, L-dopa-responsive impairment of motor
functions [98].
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logroups or mtDNA point mutations, but not all of them could be
conﬁrmed in other studies (rev. in refs. [6,86]). Clearly, maternally
inherited mtDNA mutations seem to be rarely associated with PD. By
using the cybrid technique it has been observed that mtDNA from PD
patients induces a complex I defect in healthy recipient cells, leading
to the conclusion that complex I deﬁciency at least in some PD
patients might be a systemic phenomenon [99–101]. To generate
cybrid (which stands for cytoplasmic hybrid) cells, cultured human
cells are depleted of mtDNA by long-term exposure to ethidium
bromide. The resulting cells are then fused with platelets from PD
patients or controls to re-introduce mtDNA. This approach has been
challenged by another group using cybrid cells, reporting that
alterations in respiratory chain activity do not correlate with PD
mtDNA [102].
So far, there is no clear evidence that mtDNA mutations are the
primary culprit for PD. MtDNA mutations rather occur in the context
of increasing cellular stress and decreasing ﬁdelity of cellular stress
defence systems. Notwithstanding, clonal expansion of these muta-
tions can functionally impair the respiratory capacity and thus
precipitate degeneration of vulnerable neuronal populations.
2.1. Familial PD and mitochondria
Since 1997 when α-synuclein was described as the ﬁrst gene
associated with familial PD, four other genes have conclusively been
linked to autosomal recessive (parkin, PINK1, DJ-1) or dominant
(LRRK2) parkinsonism (Table 1; for reviews on PD genetics see refs.
[3,103–106]). Mutations in ATP13A2, encoding a P-type lysosomal
ATPase, were identiﬁed in two kindreds with Kufor-Rakeb syndrome,
a multisystemic neurodegenerative disorder which in addition to
juvenile/early-onset parkinsonism shows pyramidal tract dysfunc-
tion and cognitive impairment [107]. However, ATP13A2 mutations
have also been found in rare cases with juvenile parkinsonism and
only mild additional, atypical features [108].
Familial variants of PD account for up to 10% of PD cases. They
usually, but not exclusively, show an early onset of symptoms and are
in essence clinically indistinguishable from sporadic PD [103,106].
Remarkably, what we know so far about the function and dysfunction
of PD genes conﬁrms the relevance of the biochemical alterations
found in sporadic PD, i.e., mitochondrial dysfunction, oxidative stress
and a dysbalance in protein homeostasis characterized by an increase
in protein misfolding and aggregation accompanied by an impaired
removal of misfolded proteins. Indeed, several PD genes have been
associated with mitochondrial integrity and cellular stress response
and quality control systems (rev. in refs. [109–114]). Thus, insight into
the function of PD genes can promote our understanding of the
molecular causes of PD and help to focus research on key biochemical
pathways.
2.1.1. PINK1
2.1.1.1. PINK1 and mitochondrial function. Mutations in the PINK1
(PTEN-induced putative kinase) gene are the second most common
cause of autosomal recessive, early-onset parkinsonism after parkinTable 1
PD-associated loci and genes with conclusive evidence.
PD locus Chromosomal localization Gene product Mode of inheritance
PARK1/4 4q21-q23 α-synuclein autosomal dominant
PARK2 6q25-q27 parkin autosomal recessive
PARK6 1p36-p35 PINK1 autosomal recessive
PARK7 1p36 DJ-1 autosomal recessive
PARK8 12p11-q13 LRRK2 autosomal dominant
PARK9 1p36 ATP13A2 autosomal recessivemutations [115]. PINK1 is a 581 amino acid protein with an N-
terminal mitochondrial targeting sequence and a serine/threonine
kinase domain (rev. in refs. [116]). Most pathogenic mutations are
missense mutations which cluster to the kinase domain and have
been shown to impair the kinase activity, which is essential for the
neuroprotective activity of PINK1. Increased PINK1 expression confers
protection from apoptotic cell death in various stress paradigms, and
loss of PINK1 function increases the vulnerability of cells to stress-
induced cell death [115,117–120]. The effects of PINK1 deﬁciency on
mitochondrial function and morphology are multifaceted, comprising
decreases in mitochondrial membrane potential, complexes I and IV
activities, ATP production, mitochondrial import and mtDNA levels,
increases in ROS production and abnormal ultrastructural mitochon-
drial morphology [120–135]. The cause of all the effects observed and
their timely order is still a matter of intense discussion. Morais et al.
recently reported that disruption of complex I activity is an early
event upon PINK1 loss of function, responsible for mitochondrial
membrane depolarization, increased sensitivity to apoptotic stress
and synaptic transmission deﬁcits, exempliﬁed by an impaired
mobilization of reserve pool vesicles after rapid stimulation in Dro-
sophila neuromuscular junctions [132]. Ghandi et al. demonstrated
that impaired respiration in PINK1-deﬁcient neurons can be restored
by providing substrates of complexes I and II, implying that
respiratory complexes are intact [121]. They observed that PINK1
deﬁciency causes a dysbalance of calcium homeostasis with a higher
basal mitochondrial calcium concentration andmitochondrial calcium
overload under stress conditions, which was traced back to a
dysfunction of the Na+/Ca2+ exchanger at the inner mitochondrial
membrane. The Na+/Ca2+ exchanger mediates extrusion of calcium
from mitochondria, but so far has not been characterized on a
molecular level. Thus, the mechanism of the functional interaction
between PINK1 and this exchanger could not be analyzed. However,
the data suggest that the impairment of mitochondrial calcium efﬂux
promotes ROS production that inhibits glucose uptake, resulting in
reduced substrate delivery and respiration. The dysbalance in calcium
homeostasis was placed at the top of these events, as substrate supply
could overcome impaired respiration and reduction of ROS produc-
tion restored glucose uptake, but neither substrate provision nor ROS
reductionwas able to affect mitochondrial calcium overload in PINK1-
deﬁcient cells [121]. Alterations in calcium homeostasis were also
observed in cultured cells co-expressing a pathogenic PINK1 mutant
(W437X) and A53T α-synuclein [128]. In this model, mutant PINK1
aggravated mitochondrial damage induced by α-synuclein, such as
mitochondrial membrane depolarization and increasedmitochondrial
size with loss of cristae, and in addition decreased cellular ATP
production. Interestingly, a blocker of mitochondrial calcium inﬂux
completely restored mitochondrial membrane potential and ATP
production in cells expressingmutantα-synuclein andmutant PINK1.
Weihofen et al. recently linked PINK1 to mitochondrial trafﬁcking
[131]. Immunopuriﬁcation of PINK1 from a mitochondria-enriched
fraction of HEK293-FT cells expressing FLAG-tagged PINK1 and
subsequent mass spectrometry of PINK1 complexes revealed that
PINK1 interacts with the atypical GTPase miro, implicated in
mitochondrial trafﬁcking, and the inner mitochondrial membrane
protein mitoﬁlin, which has been described to control cristae
morphology [136]. Miro is an outer mitochondrial membrane protein
which interacts with the adaptor protein milton to link kinesin-1
heavy chains to mitochondria for their anterograde axonal transport
(rev. in refs. [137,138]). Overexpression of either miro or milton
recruited PINK1 to mitochondria. Even the mitochondrial localization
of mutant PINK1 lacking the N-terminal mitochondrial targeting
sequence (Δ1–111) was markedly increased by miro or milton.
Moreover, increased expression of miro or milton could rescue
alterations in mitochondrial morphology in PINK1-deﬁcient cells. It
will now be interesting to address the question whether mitochon-
drial transport is impaired in PINK1-deﬁcient neurons and whether
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activity of PINK1.
2.1.1.2. PINK1 substrates. Two putative PINK1 substrates have been
identiﬁed to date by afﬁnity puriﬁcation approaches. Pridgeon et al.
found that PINK1 phosphorylates mitochondrial TRAP1 (TNFR-
associated protein 1; heat shock protein 75) and that the protective
activity of PINK1 against oxidative stress is dependent on TRAP1
phosphorylation [139]. Plun-Favreau et al. provided evidence for a
functional link beween PINK1 and HtrA2/Omi, a mitochondrial serine
protease which is released to the cytosol by apoptotic stimuli and
interacts with IAPs (inhibitor of apoptosis proteins). They showed
that PINK1 expression is important for phosphorylation of HtrA2/Omi
on serine 142, which is most likely mediated by the p38 stress kinase
pathway, but depends on a direct interaction of HtrA2/Omi with
PINK1 [140]. Thus, PINK1 might serve as an adaptor between HtrA2/
Omi and the p38 kinase. Phosphomimetic HtrA2/Omi mutants were
characterized by an increase in protease activity accompanied by an
enhanced ability to protect cells from rotenone- or 6-OHDA-induced
stress. This led the authors to conclude that PINK1 and HtrA2/Omi act
in the same pathway. The effects downstream of phosphorylated
HtrA2/Omi are not well understood, but it seems plausible that
HtrA2/Omi is involved in the quality control of intermembrane space
proteins, either by degrading misfolded and damaged proteins or by
transducing a stress response signal, similarly to its bacterial
homologs DegP and DegS [141]. HtrA2/Omi is an attractive candidate
for PD, since HtrA2/Omi loss-of-function mice show neurodegenera-
tion with parkinsonian features, indicating that HtrA2/Omi can serve
a neuroprotective function [142,143]. Mutations in the gene encoding
HtrA2/Omi have been reported in PD patients [144,145], however,
linkage evidence is lacking to proof pathogenicity [146,147].
2.1.1.3. Subcellular localization of PINK1. PINK1 has been reported to
reside in themitochondrial intermembrane space, the inner and outer
mitochondrial membrane and in the cytosol, and so far it is not clear
how the different ﬁndings can be explained [119,139,140,148–156]. It
is conceivable that the destination of PINK1 is dependent on speciﬁc
cellular conditions, a phenomenon which could contribute to the
regulation of PINK1 activity. A limitation in the analysis of PINK1
trafﬁcking is the lack of antibodies which efﬁciently detect endoge-
nous PINK1 in neurons. Consequently, most studies are performed
with overexpressed PINK1, which may create artifacts by overloading
the mitochondrial import machinery. It has been demonstrated that
the N-terminal 34 or 77 amino acids of PINK1 are sufﬁcient to confer
mitochondrial targeting [151,153]. In addition to full-length PINK1
(66 kDa) at least two proteolytically processed variants of 55 and 46
kDa can be found, suggesting cleavage of PINK1 by mitochondrial
processing peptidases. In conclusion, there are still many open
questions regarding (1) the precise subcellular localization and origin
of different PINK1 species, i.d. whether smaller PINK1 species occuring
in the cytosol have been N-terminally processed by mitochondrial
peptidases or result from cytosolic proteolysis, (2) conditions that
might inﬂuence its targeting and (3) whether the localization in
different compartments affects the biochemical features and func-
tional activity of PINK1. Intriguingly, a PINK1 mutant lacking the N-
terminal mitochondrial targeting sequence (Δ1–111) has recently
been shown to provide protection against MTPT-induced toxicity
similarly to wildtype PINK1 both in cultured primary cortical neurons
and mice [119].
2.1.2. Parkin
2.1.2.1. Parkin and ubiquitylation pathways. In 1998, mutations in
the parkin gene were identiﬁed as a cause of autosomal recessive PD
with juvenile onset in Japanese families [157]. Since then, more than
hundred different mutations have been described in patients ofdiverse ethnic backgrounds, accounting for the majority of autosomal
recessive parkinsonism [158,159]. The parkin gene encodes a
cytosolic 465 amino acid protein with a ubiquitin-like domain (UBL)
at the N-terminus and a RBR domain close to the C-terminus,
consisting of two RING ﬁnger motifs which ﬂank a cysteine-rich in-
between RING ﬁnger domain. The presence of the RBR domain
suggested that parkin has an E3 ubiquitin ligase activity, mediating
the covalent attachment of ubiquitin to substrate proteins. A well
known function of ubiquitin is to target substrates for degradation by
the proteasome, which requires a chain of at least four ubiquitin
moieties in length. Genetic and biochemical studies revealed that
pathogenic mutations induce a loss of parkin function, leading to the
hypothesis that the accumulation of parkin substrates causes
neurotoxicity and results in the death of dopaminergic neurons.
From yeast-two-hybrid and pull-down approaches a long list of
putative parkin substrates has emerged (rev. in ref. [160]). Curiously,
these substrates do not ﬁt into a common pathway and so far did not
contribute mechanistic insight into the functional role of parkin.
Moreover, data on the accumulation of putative parkin substrates in
parkin knockout mice or brains from patients carrying parkin
mutations are conﬂicting. There is increasing experimental evidence
that parkin can induce proteasome-independent ubiquitylation
[161–166]. Depending on the number of ubiquitin moieties attached
and the mode of ubiquitin linkage, ubiquitylation serves a remarkably
wide range of physiological functions (rev. in refs. [167–170]).
Ubiquitin harbors seven lysine residues, which in principle can all
engage in the formation of polyubiquitin chains. Ubiquitin linkage via
lysine 48 most commonly targets proteins for proteasomal degrada-
tion, while linkage via lysine 63 has several regulatory roles,
implicated in signal transduction, DNA repair, membrane protein
trafﬁcking, endocytosis and autophagy. In addition, monoubiquityla-
tion andmultiplemonoubiquitylation of a substrate protein can occur,
which also control various physiological processes. Under experi-
mental conditions, parkin can apparently catalyze different modes of
ubiquitylation, however, it is currently not clear, whether the
multifaceted activity of parkin under in vitro conditions is of relevance
in the physiological context.
2.1.2.2. Parkin: an all-purpose neuroprotective protein. The most
impressive and reproducible activity of parkin is its wide neuropro-
tective capacity. Parkin can protect cells against a remarkably wide
spectrum of stressors, including mitochondrial dysfunction, excito-
toxicity, endoplasmic reticulum stress, proteasome inhibition and
overexpression of α-synuclein, tau, Aβ peptide or expanded poly-
glutamine fragments (rev. in refs. [160,171]). In linewith a central role
of parkin in maintaining neuronal viability, parkin gene expression is
up-regulated in various stress paradigms [164,172–175]. Recent
research revealed that the neuroprotective activity of parkin is
associated with proteasome-independent ubiquitylation [162,164].
However, this ﬁnding does not exclude the possibility that parkin can
target some substrates for proteasomal degradation.
Notably, parkin could play a more general role in the pathogenesis
of sporadic PD based on the fact that parkin is prone to misfolding
(rev. in refs. [171,176]). We and others could show that several
pathogenic mutations as well as severe oxidative stress induce the
formation of non-native, non-functional parkin [163,177–187].
Remarkably, LaVoie et al. could demonstrate that misfolded parkin
occurs in the substantia nigra of sporadic PD patients [188]. In support
of this concept, parkin can be inactivated by nitrosative stress and
S-nitrosylated parkin has also been detected in the brains of sporadic
PD patients [189,190].
2.1.2.3. Parkin and mitochondria. One of the ﬁrst links between
parkin and mitochondria was provided by Darios et al. who observed
that parkin preventsmitochondrial swelling and cytochrome c release
in ceramide-treated cells [191]. Another important ﬁnding of this
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the outer mitochondrial membrane, both in parkin-overexpressing
cells and mouse brain. Prevention of cytochrome c release by parkin
was recently conﬁrmed by using a cell-free in vitro assay. Berger et al.
presented evidence that the expression levels of parkin are inversely
correlated with cytochrome c release induced by BH3 domains of pro-
apoptotic proteins [192]. Interestingly, PINK1, which seems to be
functionally linked with parkin (see Section 2.2.4), had no effect on
cytochrome c release. Moreover, the association of parkin with
mitochondria is apparently not sufﬁcient for the inhibition of evoked
cytochrome c release; parkin had to be expressed in life cells prior to
isolation of mitochondria to prevent cytochrome c release [192].
Localization of parkin at the outer mitochondrial membrane has also
been observed by Stichel et al. who performed an ultrastructural
analysis of adult mouse brain [193]. Kuroda et al. found parkin
exclusively inside mitochondria in proliferating SH-SY5Y cells, where
it binds to the mitochondrial transcription factor TFAM to stimulate
mitochondrial replication and transcription [194]. When cells were
placed under differentiated or quiescent (treatment with anti-
proliferative agents) conditions, parkin moved to the cytoplasm via
the permeability transition pore. By using a chromatin immunopre-
cipitation approach, binding of endogenous parkin to mtDNA in
proliferating, but also differentiated SH-SY5Y cells and even mouse
brain tissue was recently demonstrated by Rothfuss et al. [195]. The
authors of this study conﬁrmed that ectopic expression of parkin
enhances replication of the mitochondrial genome and transcription
of mitochondrial genes. In addition, parkin was found to protect
mtDNA from oxidative damage and to stimulate mtDNA repair [195].
It will now be important to address the questions of how parkin can
enter mitochondria, which conditions enhance its mitochondrial
localization and which target(s) parkin may have inside mitochon-
dria. Whatever the precise mechanism might be, the capacity of
parkin to protect cells againstmitochondrial toxins was demonstrated
in various cellular and animal models [164,191,196–201].
A proteomic approach using ventral midbrain of parkin knockout
mice revealed a decreased abundance of some proteins involved in
mitochondrial function (subunits of complexes I and IV) and the
oxidative stress response [202]. Of note, the authors of this study
presented evidence for a reduced respiratory capacity of striatal
mitochondria isolated from parkin knockout mice, while the gross
mitochondrial morphology appeared normal. Another proteome
study indicated that a high proportion of differentially expressed
proteins in cortical or striatal tissue derived from parkin knockout
mice was related to energy metabolism, probably reﬂecting an
adaptive regulation of bioenergetics in response to parkin loss of
function [203]. Stichel et al. performed a comprehensive ultrastruc-
tural analysis of mitochondrial morphology in parkin knockout mice,
A30P/A53T α-synuclein transgenic mice, and double mutant mice
(parkin knockout×A30P/A53T α-synuclein transgenic mice) and
reported age- and tissue-speciﬁc changes in both mono- and
double-mutant mice [204]. None of these transgenic mice developed
overt motor disabilities or gross histopathological abnormalities.
However, marked alterations in mitochondrial architecture, such as
dilated and disorganized cristae, were observed in the substantia
nigra and cortex, but not in the skeletal muscle cells of aged (12–14
months) double-mutant mice. Even though cortical mitochondria
were signiﬁcantly damaged, the respiration capacity of complex I
was only compromised in the substantia nigra, suggesting that
dopaminergic neurons are particularly vulnerable to mitochondrial
damage.
Several studies analyzed mitochondrial features in tissues from
parkin-mutant patients. Müftüoglu et al. measured complexes I and IV
activities in mitochondria isolated from leukocytes [205]. A signiﬁcant
decrease (by about 60%) in complex I activity was found both in
patients with parkin mutations and sporadic PD patients, whereas
complex IV activity was only reduced in sporadic PD patients.Cultured ﬁbroblasts from parkin mutant patients showed morpho-
logical and functional mitochondrial defects, i.e. a decrease in the
membrane potential (by 30%), complex I activity (by 45%), ATP
production (by 58%) and an increase in rotenone-induced mitochon-
drial fragmentation [206]. In the study of Rothfuss et al. parkinmutant
ﬁbroblasts were characterized by a 22% reduction in the mtDNA copy
number and an increased vulnerability to oxidative stress-induced
mtDNA damage [195].
2.1.2.4. A functional link between parkin and PINK1. Similarly to
parkin knockout mice, PINK1-deﬁcient mice do not display degener-
ation of dopaminergic neurons, but only some mild alterations in
dopaminergic neurotransmission. In PINK1 knockout mice (Δexons
4–7) a decrease in evoked striatal dopamine release and subsequent
impairment of synaptic plasticity has been observed [207]. Curiously,
an increase of extracellular striatal dopamine occurred in some parkin
knockout mice (Δexon3; [208,209]. Gautier et al. reported a subtle
increase in larger, but ultrastructurally normal mitochondria, a mild
reduction in mitochondrial respiration in the striatum of young (3–4
months) and in the cortex of aged (22–24 months) PINK1 knockout
mice, which, however, did not lead to reduced ATP levels [122]. Even
in aged PINK1 knockout mice levels of oxidative stress markers were
unchanged. In a different PINK1 knockout mouse line Gispert et al.
observed progressive reduction of body weight and spontaneous
locomotor activity in the absence of nigrostriatal degeneration [124].
Whether locomotor deﬁcits in these mice were L-dopa responsive has
not been reported. Furthermore, import of pre-proteins in liver
mitochondria from these PINK1-deﬁcient mice was impaired in an
age-dependent manner [124]. This is an interesting observation
which raises the question whether PINK1 per se has an effect on
mitochondrial import or whether the defective import observed in
PINK1-deﬁcient mice is a consequence of the reduced mitochondrial
membrane potential.
In contrast to parkin and PINK1 knockout mice, Drosophila null
mutants show a striking and remarkably similar phenotype, charac-
terized by reduced life span, male sterility, and locomotor defects due
to apoptotic ﬂight muscle degeneration [210–214]. The earliest
manifestation of muscle degeneration and defective spermatogenesis
was mitochondrial pathology, exempliﬁed by swollen mitochondria
and disintegrated cristae [210]. Strikingly, parkin could compensate
for the PINK1 loss-of-function phenotype, but not vice versa, implying
that PINK1 and parkin function in a common genetic pathway with
parkin acting downstream of PINK1 [211–213]. Subsequent studies in
Drosophila suggested that parkin and PINK1 may have a possible role
in modulating mitochondrial morphology and dynamics [215–218]
(see Fig. 1 for an overview of mitochondrial dynamics). In ﬂies, the
parkin or PINK1 ﬂight muscle phenotype was suppressed by an
increase inmitochondrial ﬁssion or a decrease in fusion, leading to the
conclusion that the PINK1/parkin pathway promotes mitochondrial
ﬁssion. In parallel, we performed studies in cultured human cells and
conﬁrmed that parkin can compensate for the alterations in
mitochondrial morphology induced by siRNA-mediated down-regu-
lation of PINK1 [134]. Notably, transient silencing of parkin in
dopaminergic SH-SY5Y showed a mitochondrial phenotype remark-
ably similar to that of PINK1 deﬁciency, characterized by a marked
increase in mitochondrial fragmentation and a decrease in overall ATP
production [135]. Both the morphological and functional deﬁcits
could be prevented by the enhanced expression of the fusion-
promoting proteins Mfn2 or OPA1. Likewise, a dominant negative
mutant of the ﬁssion-promoting protein Drp1 was protective,
suggesting that a decrease in mitochondrial fusion or an increase in
ﬁssion is associated with a loss of parkin or PINK1 function. The
following ﬁndings established that an increase in mitochondrial
fragmentation is responsible for the alterations observed in parkin- or
PINK1-deﬁcient cells. First, the mitochondrial phenotype in parkin- or
PINK1 deﬁcient cells was not observed in Drp1-deﬁcient cells. Second,
Fig. 1. Parkin, PINK1 and mitochondrial dynamics. (A) Key players of the mitochondrial fusion and ﬁssion machinery. For reviews on mitochondrial dynamics, see refs. [319-322].
(B) Transient down-regulation of parkin or PINK1 by RNA interference induces alterations in mitochondrial morphology in human SH-SY5Y cells. Control siRNA-transfected cells
show a network of tubular mitochondria. Parkin or PINK1 loss of function results in mitochondrial fragmentation, which also occurs in Mfn2-deﬁcient cells due to an relative
increase in mitochondrial ﬁssion.
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Drp1. At the same time Sandebring et al. reported very similar
ﬁndings for a stable PINK1 knockdown in human dopaminergic M17
cells [130]. These authors used ﬂuorescence recovery after photo-
bleaching (FRAP) to show that PINK1 can reduce mitochondrial
fragmentation induced by rotenone in a kinase-dependent fashion,
whereas PINK1-deﬁcient cells displayed a lower mitochondrial
connectivity. In line with a study by Dagda et al. and our observations,
knockdown of Drp1 prevented mitochondrial fragmentation caused
by PINK1 loss of function [129,135]. Of note, mitochondrial
fragmentation observed in parkin- or PINK1-deﬁcient cells was not
a consequence of increased apoptotic cell death [130,135]. The
activity of Drp1 is regulated by posttranslational modiﬁcations,
therefore Sandebring et al. analyzed whether in PINK1-deﬁcient
cells the phosphorylation status of Drp1 might be altered. Theyobserved that a loss of PINK1 function is associated with a decrease in
phospho-Drp1 levels and an increase in Drp1 GTPase activity.
Calcineurin is a phosphatase known to dephosphorylate Drp1 at
serine 637 [219], consequently, Sandebring et al. tested PINK1-
deﬁcient cells for expression levels and activity of calcineurin. They
found that calcineurin activity was signiﬁcantly increased in PINK1
knockdown cells, while expression levels were not affected. Inter-
estingly, the calcineurin inhibitor FK506 could rescue mitochondrial
fragmentation caused by a loss of PINK1 function. These ﬁndings add
to the notion that calcium homeostasis is impaired in PINK1-deﬁcient
cells [121,128].
Obviously, the ﬁndings in mammalian parkin- or PINK1-deﬁcient
cells are strikingly different to those reported in the ﬂy models. How
can these discrepancies be explained? To address this question
experimentally, we performed a comparative analysis of the
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and insect cells [135]. Notably, mitochondrial fragmentation turned
out to be an early response to parkin or PINK1 loss of function which
also occurred in primary mouse neurons and Drosophila S2 cells. In
addition, the mitochondrial phenotype was more pronounced after
transient silencing in comparison to stable knockdown conditions,
suggesting that compensatory mechanisms can rapidly be activated.
This might explain why mitochondrial fragmentation in PINK1-
deﬁcient cells was observed in some, but not all studies and why
parkin or PINK1 knockout mice do not display gross alterations in
mitochondrial morphology. It is conceivable that compensatory
strategies might not be sufﬁcient to maintain mitochondrial integrity
in parkin- or PINK1-deﬁcient cells under stress conditions. Indeed,
different studies reported mitochondrial fragmentation and function-
al deﬁcits in cultured skin ﬁbroblasts from parkin- or PINK1-mutant
patients upon cellular stress [126,134,206].
What can we learn from the discrepant ﬁndings in Drosophila
and mammalian models? First, it seems rather unlikely that parkin
and PINK1 directly regulate mitochondrial dynamics. Regulation of
mitochondrial dynamics might be more sophisticated in mammals
[220], but in general, the fusion and ﬁssion machinery is highly
conserved. Thus, it is implausible that parkin/PINK1 promote ﬁssion
in ﬂies and prevent ﬁssion in mammals. Second, the Drosophila
models without any doubt have a lot of advantages, but we should
keep in mind that for some aspects there seem to be differences
between ﬂies and humans. In particular, Drosophila ﬂight muscles
and eyes are highly specialized tissues. We observed that an increase
in mitochondrial fragmentation occurs early upon parkin/PINK1
silencing both in cultured human and Drosophila cells [135]. Thus,
the most plausible explanation for the discrepant ﬁndings is that the
compensatory strategies in ﬂies and mammals are different. The
accumulation of damaged mitochondria in parkin/PINK1-deﬁcient
ﬂies might be a stimulus to activate fusion in an attempt to dilute
these dysfunctional mitochondria. However, in tissues with high
energy demands, such as ﬂight muscles or spermatids, this strategy
might not be beneﬁcial in the end, as increased fusion eventually
leads to the contamination of the whole mitochondrial network with
dysfunctional contents [221]. This might explain why parkin/PINK1
null ﬂies show a phenotype in such tissues that can be rescued by
increasing ﬁssion, possibly favoring the elimination of dysfunctional
mitochondria by autophagy [222]. In support of this concept, a
recent study proposed that parkin can promote mitophagy, i.e., the
autophagic clearance of dysfunctional mitochondria [223]. Narendra
et al. presented evidence that treatment of HEK293 cells with
the uncoupler CCCP (carbonyl cyanide 3-chlorophenylhydrazone)
induces recruitment of parkin to depolarized mitochondria within
one hour. The authors then turned to HeLa cells, which do not
express endogenous parkin due to the localization of the parkin gene
within FRA6E (6q26), a common fragile site of the human genome
that is frequently mutated in ovarian tumors [224]. After 48 h of
CCCP treatment, no mitochondria were detectable by immunocyto-
chemistry in HeLa cells overexpressing YFP-parkin, suggesting that
parkin can induce the removal of damaged mitochondria. Clearance
of depolarized mitochondria by parkin did not occur in autophagy-
deﬁcient ATG5 knockout mouse embryonic ﬁbroblasts, which
indicates that autophagosome formation is essential for this effect.
The study by Narendra et al. provided fundamental new insight into
the role of parkin in mitochondrial quality control and opens new
avenues for further investigations. First, a role in regulating
mitophagy has to be proven for endogenous parkin. Likewise, are
pathogenic parkin mutants impaired in this activity? However, the
most important question is whether ubiquitylation activity of parkin
is required for inducing mitophagy. Strikingly, ubiquitylation has
recently emerged as a selective targeting signal for the autophagic
clearance of various types of cargo (rev. in ref. [225]). An appealing
scenario would be that parkin ubiquitylates a speciﬁc substrate atthe mitochondrial membrane in response to stress conditions
associated with a decrease of the mitochondrial membrane
potential. Where and when could PINK1 enter the stage? Loss of
PINK1 function has recently been reported to promote autophagy
and mitophagy in SH-SY5Y cells, which was accompanied by an
increase in mitochondrial ﬁssion and ROS production [129].
Dominant-negative Drp1 did not reduce mitochondrial ROS produc-
tion, but scavenging superoxide anions inhibited autophagy in
PINK1-deﬁcient cells, suggesting that ROS are necessary for both
mitochondrial fragmentation and autophagy. Interestingly, siRNA-
mediated down-regulation of ATG7 or ATG8/LC3B, two proteins
essential for autophagy, did not affect mitochondrial ROS produc-
tion, but reversed mitochondrial fragmentation in PINK1-deﬁcient
cells. This ﬁnding points to a possible reciprocal interaction of the
machineries regulating mitochondrial dynamics and autophagy.
Furthermore, Dagda et al. reported that parkin overexpression
increased mitophagy in PINK1-deﬁcient cells. Thus, parkin and
PINK1 appear to have different net effects on mitophagy, whereas
the consequences of PINK1/parkin loss of function on mitochondrial
morphology and function are strikingly similar both in mammalian
and Drosophila models.
Based on the observation that PINK1 is partially located in the
cytosol, there is in principle a chance for a cytosolic rendezvous of
parkin and PINK1, possibly at the outer mitochondrial membrane.
Indeed, a direct interaction of parkin and PINK1 has been observed.
Kim et al. reported that PINK1 controls the mitochondrial localization
of parkin by directly phosphorylating parkin at threonine 175 [226].
Um et al. observed that parkin binds to PINK1 and up-regulates
expression of PINK1, which in turn reduces the solubility of parkin
[227]. Shiba et al. show that parkin directly interacts with PINK1,
leading to a stabilization of PINK1 by interference with its ubiquityla-
tion and proteasomal degradation [228]. These are interesting
observations, however they are based on the overexpression of
parkin and PINK1. Studies in both Drosophila andmammalian cells are
consistent in the ﬁnding that parkin can rescue PINK1 deﬁciency
[134,135,211–213], thus parkin seems to act downstream of PINK1.
However, for a functional interaction parkin and PINK1 not necessar-
ily have to interact physically. It is also conceivable that PINK1
phosphorylates a mitochondrial protein upon stress which can
activate a pathway converging at parkin or at a target downstream
parkin. Obviously, PINK1 is not essential for parkin function, and
consequently, the functional interaction of PINK1 and parkin might
not ﬁt into a simple, linear pathway. In line with a more complex link
between parkin and PINK1, parkin can prevent evoked mitochondrial
cytochrome c release, while PINK1 cannot [192]. Clearly, more studies
are needed to unravel the role of parkin and PINK1 in mitochondrial
protection, remodeling and clearance and the mechanism underlying
their functional interaction.
Three recent studies in Drosophila addressed the role of HtrA2/
Omi as another possible player in the PINK1/parkin game. While the
ﬂy studies are in agreement on the functional interaction of PINK1
and parkin, this is strikingly different for the role of HtrA2/Omi. Using
ectopic expression in the Drosophila eye, Whithworth et al. observed
that HtrA2/Omi genetically acts downstream of PINK1, but functions
independently of parkin. They also showed that rhomboid-7 (pre-
senilin-associated rhomboid-like [PARL] in mammals) is required to
cleave the precursor forms of both PINK1 and HtrA2/Omi [229].
However, Yun et al. reported that HtrA2/Omi null mutants do not
show defects in mitochondrial integrity [230]. In addition, they found
no evidence for a genetic interaction between PINK1 and HtrA2/Omi
in loss-of-function studies. Conversely, Tain et al. found mild
mitochondrial defects in HtrA2/Omi null ﬂies and observed that
HtrA2/Omi can partially substitute for PINK1 loss of function [231].
PINK1/HtrA2/Omi double mutant ﬂies showed a phenotype identical
to that of PINK1 mutants, while the phenotype of parkin/HtrA2/Omi
double mutants was stronger than that of either mutant alone, which
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downstream effectors of PINK1, but act in parallel pathways.
2.1.3. DJ-1
Mutations in the DJ-1 gene, encoding a 189-amino acid protein,
have been associated with rare cases of early onset autosomal
recessive PD [232]. A large deletion and a missense mutation
(L166P) leading to the rapid degradation of the mutant protein
were the ﬁrst mutations identiﬁed in patients, indicating that a loss of
DJ-1 function can cause parkinsonism (rev. in refs. [233]). DJ-1
belongs to the ThiJ/PfpI family and shares structural similarities with
the stress-inducible Escherichia coli chaperone Hsp31 [234].
Various functions have been ascribed to DJ-1. Clearly, over-
expression of DJ-1 protects neurons from oxidative stress-induced
damage and DJ-1 deﬁciency renders cells more susceptible to
oxidative injury [197,235–242]. DJ-1 is converted into a more acidic
pI variant in response to oxidative stress, due to the formation of
cysteine–sulﬁnic acid at cysteine 106 [243–245]. Notably, cysteine
106 is essential for the neuroprotective activity of DJ-1
[237,244,246,247]. Studies on the subcellular localization of DJ-1
reported the presence of DJ-1 in cytosolic, mitochondrial and nuclear
compartments; mitochondrial localization of DJ-1 was enhanced by
oxidative stress [248–250]. Substitution of cysteine 106 by alanine
interfered with both mitochondrial localization and protection
against mitochondrial toxins [244]. Within mitochondria endogenous
DJ-1 was found in the matrix and intermembrane space [251]. Junn et
al. recently observed that endogenous DJ-1 translocates to mitochon-
dria (within 3 h) and the nucleus (within 12 h) of human
neuroblastoma cells in response to oxidative stress [252]. Interest-
ingly, mitochondrial targeting of DJ-1 via fusion to a mitochondrial
targeting signal sequence increased its neuroprotective activity. The
authors of this study reported that the mutation of cysteines at
positions 106, 53 or 46 had no impact on the mitochondrial
localization of DJ-1 upon oxidative stress.
What might be the function of mitochondrial DJ-1? Isolated
mitochondria from DJ-1 knockout mice showed a twofold increase in
hydrogen peroxide accompanied by a reduction in mitochondrial
aconitase activity, indicating a deﬁcit in scavenging mitochondrial
ROS [253]. By employing recombinant DJ-1 and mass spectrometry
analysis, Andres-Mateos et al. demonstrated that DJ-1 is an atypical
peroxiredoxin-like peroxidase and that cysteine 106 is the principal
target for sulﬁnic acid formation.
Of note, DJ-1 could not compensate for the mitochondrial
alterations observed in parkin- or PINK1-deﬁcient cells, neither in
the Drosophila model nor in cultured human cells, suggesting that it
does not function within PINK1/parkin pathway [134,213].
2.1.4. α-Synuclein
Three missense mutations (A53T, A30P, E46K) as well as genomic
duplication and triplication of the gene encoding α-synuclein have
been identiﬁed in rare cases of familial PD [254–260]. α-Synuclein is
the major component of Lewy bodies, therefore providing the most
obvious link between sporadic and familial PD [1]. Despite enormous
efforts, little is known about the physiological function of α-
synuclein and its mechanism of toxicity. α-Synuclein is a 140-
amino acid protein which is abundantly expressed in the central
nervous system. Its enrichment in presynaptic terminals and its
association with vesicles suggests a role in synaptic dynamics (rev. in
refs. [261,262]). α-Synuclein is a natively unfolded or intrinsically
disordered protein with considerable conformational plasticity (rev.
in refs. [263–265]). Similarly to other misfolding-prone proteins,
evidence accumulated that not the ﬁnal α-synuclein aggregates, but
rather oligomeric intermediates might be the toxic species (rev. in
refs. [176,264,266,267]). Based on observations in different model
systems various mechanisms have been proposed to explain the toxic
effects of α-synuclein (rev. in refs. [267]), including impairedendoplasmic reticulum (ER) to Golgi vesicular trafﬁcking and ER
stress [268,269], impairment of proteasomal or lysosomal protein
degradation [270–275], Golgi fragmentation [276], sequestration of
anti-apoptotic proteins into aggregates [277], and the formation of
pores on cellular membranes [278,279].
Several studies reported that a fraction of cytosolic α-synuclein
can be found at or even within mitochondria in a regio-speciﬁc
manner [280–283]. Binding of α-synuclein to mitochondria was
enhanced by cytosolic acidiﬁcation [284]. Perihar et al. observed
cytochrome c release and an increase in mitochondrial calcium and
nitric oxide in response to the association of α-synuclein with
mitochondria [285]. Devi et al. showed that the N-terminal 32 amino
acids of α-synuclein harbor a cryptic mitochondrial targeting signal
directing α-synuclein to the inner mitochondrial membrane where it
associates with complex I [286]. As a result, α-synuclein decreased
complex I activity and increased ROS production in human fetal
dopaminergic primary neuronal cultures overexpressing wildtype α-
synuclein. Overexpression of A53T α-synuclein accelerated these
effects. To substantiate their ﬁndings, Devi et al. determined the
amount of mitochondrial α-synuclein in human brain and found a
signiﬁcant accumulation of α-synuclein in the substantia nigra and
striatum from PD patients.
Further evidence for mitochondrial alterations was found in
cellular and mouse models overexpressing wildtype or mutant α-
synuclein, including ultrastructural abnormalities, reduced COX and
complex IV activity, a decrease in the mitochondrial membrane
potential, oxidation of mitochondria-associated metabolic proteins,
and an increased sensitivity to mitochondrial toxins, possibly by
increasing α-synuclein aggregation [204,287–294]. However, an
increase in sensitivity to mitochondrial toxins in α-synuclein over-
expressing mice was not observed in all studies [295,296]. α-
Synuclein knockout mice have been described to be resistant or less
sensitive to mitochondrial toxins [297–301]. Interestingly, α-synu-
clein knockout mice were reported to have qualitative and quantita-
tive mitochondrial lipid abnormalities with a decrease in cardiolipin
content, which was associated with a reduction in complex I/III
activity [302]. From a recent yeast study it emerged that mitochondria
play an important role in mediating the toxic effects of α-synuclein
[303]. Buttner et al. showed that expression of wildtype or A53T
mutant α-synuclein in chronologically aged yeast cells accelerates
apoptosis and ROS production, which did not occur in strains lacking
mitochondrial DNA.
All in all, increased α-synuclein expression as well as α-synuclein
deﬁciency seems to be associated with mitochondrial abnormalities.
However, at present it is difﬁcult to reconcile the manifold observa-
tions in a unifying theory about a role ofα-synuclein in mitochondrial
function.
2.1.5. LRRK2
Mutations in the LRRK2 gene are the most common cause of
genetic PD; they are responsible for the majority of autosomal
dominant PD typically associated with late-onset and are also found
in some cases which would have been classiﬁed as sporadic PD
[304,305]. The LRRK2 gene encodes a large multidomain protein
of 2527 amino acids, including a kinase domain related to the
mixed lineage kinase family, a Roc domain (Ras in complex
proteins) with similarity to the Ras/GTPase superfamily, a COR
domain (C-terminal of Roc), a WD40-repeat domain and leucine-
rich repeats (rev. in refs. [306–308]). Some pathogenic mutations
seem to increase the kinase activity of LRRK2 in vitro, assessed by
autophosphorylation or phosphorylation of generic substrates,
which may suggest a toxic gain of function mechanism [309–
312]. So far, our knowledge about the physiological function and
the pathological mechanism of LRRK2 is limited. LRRK2 can bind to
the outer mitochondrial membrane in mammalian brain and about
10% of overexpressed LRKK2 was found in association with the
Fig. 2. Mitochondrial alterations associated with PD.
38 K.F. Winklhofer, C. Haass / Biochimica et Biophysica Acta 1802 (2010) 29–44outer mitochondrial membrane [309,312,313]. However, it remains
to be determined whether LRRK2 has an impact on mitochondrial
integrity.
3. Perspective
Recent research on the function and dysfunction of PD-associated
genes has provided fundamental new insights into biochemical
pathways which are associated with the disease process. Moreover,
these ﬁndings established that mitochondrial dysfunction is a
common denominator of sporadic and familial PD, moving mitochon-
dria to the forefront of PD research. Manifold facets of mitochondrial
biology seem to be affected in PD (Fig. 2). Still, there will be
tremendous work ahead of us to ﬁt together the pieces of the puzzle
into a conclusive concept. Likewise, the chronological order of the
events implicated in mitochondrial damage and neuronal degenera-
tion is far from being understood.
Considering the important role of mitochondria in energy
metabolism, calcium homeostasis, cellular quality control pathways
and cell death regulation, it is tempting to speculate that mitochon-
drial dysfunction contributes to the high vulnerability of dopaminer-
gic neurons. These neurons are characterized by a high oxidative
burden resulting from dopamine metabolism and excitotoxicity,
while their antioxidative repertoire is rather limited (rev. in refs.
[18,82]). In this context it is interesting to note that regiospeciﬁc
differences in biochemical and structural parameters of brain
mitochondria have been documented. Another key player seems to
be calcium. Adult dopaminergic neurons are uniquely dependent on
voltage-dependent L-type Ca2+ channels for autonomous pacemaking
activity [314–317]. In keeping with a crucial role of mitochondria in
regulating calcium homeostasis, a dysbalance in calcium buffering
seems to be causally related to the selective degeneration of
dopaminergic neurons (rev. in refs. [318]).
Collectively, the exceptional physiological features of dopaminer-
gic neurons help to explain why mitochondrial ﬁdelity and an
effective cellular quality control and stress response management
are paramount to the survival of these neurons, particularly in an
aging individual. There is compelling evidence that at least some of
the PD-associated genes interface with these pathways . It will now be
a challenging endeavour to exploit these pathways as a rationale to
halt or delay disease progression and to move basic research into
clinical practice.
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